|
Sept 22, 2005
LSR LISTING ON NYSE BLOCKED FOR NOW,
THANKS TO THE NEW YORK STOCK EXCHANGE
On September 7th, the New York Stock Exchange (NYSE)
made the unprecedented decision to postpone the
listing of Life Sciences Research (LSR), otherwise
know as Huntingdon Life Sciences, from trading on the
"big board". Although the NYSE never once, either
directly or indirectly, referenced the "threat" of
animal rights action as the reason for their decision,
that was exactly the way LSR and their political and
industry cronies chose to spin the story. Within
hours, statements were broadcast and published
worldwide, without an iota of proof, that pressure
from animal rights activists motivated the NYSE's
decision.
At the time of the announced listing, Win Animal
Rights (WAR) welcomed the attention that the potential
listing brought to LSR/HLS, a company that has not
paid dividends in years and operates under a cloak of
secrecy and deception. We know that the NYSE is
supposed to guarantee financial integrity and
transparency to countless millions of investors.
There are so many factors that make us question the
financial integrity and transparency of LSR that we
believe it could have been any one of a number of
factors that caused the NYSE to postpone the listing.
Was it the fact that no commercial bank or insurance
company in the world will deal with them? Or perhaps
the fact that their "Public Accountant" is a mystery
man who does not want to be identified? Or the fact
that their shareholder meetings are held at secret
locations in Panama and subject to cancellation with
little or no notice? Or that some of their Board
members are from third world countries with little or
no relevant industry experience? Or maybe it is LSR's
$79.5 million debt load? Any of the above might cause
a potential investor to question further. Is it any
wonder that the NYSE wants to take another look?
Or just maybe, the NYSE considered the very fact that
LSR was the object of a global campaign to shut them
down, that caused them to want to take another look at
the listing before moving forward. This willingness
to investigate further should have been applauded
around the world by thankful potential investors and
by those who value our financial stability and
integrity.
Instead, the NYSE has become the object of an intense
campaign of intimidation and harassment that has
included no less than a United States Senate
Subcommittee Chairman and no doubt the hard ball
pressure tactics of many of the giant pharmaceutical
companies and their industry lobbying groups.
Let's take a minute to thank members of the NYSE for
having the courage and integrity to stand up to
corporate and government bullies.
Please call to thank the NYSE at: 212-656-3000
Contact Ray Pellecchia, Corporate Communications:
212-656-2001
e-mail: rpellecchia@nyse.com
You can send thank you notes to NYSE's President,
Catherine Kinney:
Catherine R. Kinney
President and Co-Chief Operating Officer
New York Stock Exchange
11 Wall Street
New York, NY 10005
e-mail: ckinney@nyse.com
As long as LSR is kept off of the board, WAR will
refocus attention back on the companies, investors and
market makers that contribute to LSRI's bottom line by
continuing to deal in LSRI/HLS blood money.
Again, our thanks to the NYSE. We will of course be
watching developments as regards LSR with
great interest.
For more info contact: Win Animal Rights/W.A.R.:
govegan@optonline.net
call: 646-267-9934 or visit our website:
http://war-online.org
|
